---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006586"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:38:47.982522+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics reports Q4 net loss of $18.7M; cash $120M funds operations into Q2 2024

## Summary
- Q4 2022 net loss $18.7M vs $14.2M in Q4 2021; FY2022 net loss $66.2M vs $48.6M.
- Q4 2022 revenue $3.1M, up from $2.9M; FY2022 revenue $13.5M (vs $10.1M in 2021).
- Cash and cash equivalents $120.0M as of Dec. 31, 2022; runway into Q2 2024.
- Phase 1 hematologic trial for TSC-100/101 expected to enroll all three arms by mid-2023 with preliminary safety/biomarker data.
- Solid tumor INDs for T-Plex and two TCRs cleared; initial single-agent TCR data expected by year-end 2023.

## SEC filing metadata
- accession: 0000950170-23-006586
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/0000950170-23-006586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/tcrx-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006586
- JSON: https://secwatch.observer/filing/0000950170-23-006586.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006586.txt

## Key facts
- Earnings Releases
  TScan Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 8, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/0000950170-23-006586-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.